WINDWARD study of mirivadelgat in pulmonary hypertension associated with interstitial lung disease

Phase 2, randomised, double-blind trial in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD) comparing Mirivadelgat with Placebo (2 arms). Primary endpoint: Mean change from baseline to Week 12 in pulmonary vascular resistance. Planned start Oct 2026; status: authorised.